MX2024013807A - Soluciones acuosas de ticagrelor, metodo de fabricacion y usos - Google Patents
Soluciones acuosas de ticagrelor, metodo de fabricacion y usosInfo
- Publication number
- MX2024013807A MX2024013807A MX2024013807A MX2024013807A MX2024013807A MX 2024013807 A MX2024013807 A MX 2024013807A MX 2024013807 A MX2024013807 A MX 2024013807A MX 2024013807 A MX2024013807 A MX 2024013807A MX 2024013807 A MX2024013807 A MX 2024013807A
- Authority
- MX
- Mexico
- Prior art keywords
- ticagrelor
- aqueous
- solutions
- manufacturing
- intravenous administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2022/063185 WO2023222184A1 (en) | 2022-05-16 | 2022-05-16 | Aqueous ticagrelor solution, method of manufacturing and uses |
| EP2023055736 | 2023-03-07 | ||
| PCT/EP2023/063071 WO2023222660A1 (en) | 2022-05-16 | 2023-05-16 | Aqueous ticagrelor solutions, method of manufacturing and uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024013807A true MX2024013807A (es) | 2025-02-10 |
Family
ID=86604209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024013807A MX2024013807A (es) | 2022-05-16 | 2024-11-07 | Soluciones acuosas de ticagrelor, metodo de fabricacion y usos |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250235455A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4525931A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025515559A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20250024925A (cg-RX-API-DMAC10.html) |
| CN (1) | CN119212736A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2023271339A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3252689A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024013807A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023222660A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260113060A (ko) * | 2023-11-16 | 2026-07-21 | 하이로리스 디벨롭먼츠 에스에이 | 피부경유 관상동맥 중재술 (pci)을 겪은 환자에서 허혈성 사건의 치료, 감소 또는 예방에 사용을 위한 티카그렐러 iv |
| WO2025104274A1 (en) * | 2023-11-16 | 2025-05-22 | Hyloris Developments Sa | Ticagrelor iv for use in the prevention of thromboembolic events |
| AU2024386725A1 (en) * | 2023-11-22 | 2026-04-30 | Hyloris Developments Sa | Intravenous administration of ticagrelor compositions in a patient who was previously administered an opioid in order to treat coagulation and avoid reduced ticagrelor uptake |
| CN117919246A (zh) * | 2024-01-26 | 2024-04-26 | 重庆东得医药科技有限公司 | 一种以左西孟旦为活性成分的组合物及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3100728T3 (pl) * | 2009-05-13 | 2020-05-18 | Cydex Pharmaceuticals, Inc. | Kompozycje farmaceutyczne zawierające prasugrel i pochodne cyklodekstryny oraz sposoby ich wytwarzania i zastosowania |
| CN110917167A (zh) * | 2018-09-19 | 2020-03-27 | 河南天晟泰丰医药科技有限公司 | 替格瑞洛肠溶缓释软胶囊及其制备方法 |
| WO2021096444A1 (en) * | 2019-11-13 | 2021-05-20 | Santa Farma İlaç Sanayi̇ A.Ş. | Pharmaceutical compositions comprising ticagrelor |
-
2023
- 2023-05-16 US US18/855,499 patent/US20250235455A1/en active Pending
- 2023-05-16 EP EP23726507.9A patent/EP4525931A1/en active Pending
- 2023-05-16 JP JP2024557894A patent/JP2025515559A/ja active Pending
- 2023-05-16 CN CN202380040644.0A patent/CN119212736A/zh active Pending
- 2023-05-16 KR KR1020247041152A patent/KR20250024925A/ko active Pending
- 2023-05-16 WO PCT/EP2023/063071 patent/WO2023222660A1/en not_active Ceased
- 2023-05-16 AU AU2023271339A patent/AU2023271339A1/en active Pending
- 2023-05-16 CA CA3252689A patent/CA3252689A1/en active Pending
-
2024
- 2024-11-07 MX MX2024013807A patent/MX2024013807A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN119212736A (zh) | 2024-12-27 |
| US20250235455A1 (en) | 2025-07-24 |
| EP4525931A1 (en) | 2025-03-26 |
| JP2025515559A (ja) | 2025-05-20 |
| WO2023222660A1 (en) | 2023-11-23 |
| CA3252689A1 (en) | 2023-11-23 |
| KR20250024925A (ko) | 2025-02-20 |
| AU2023271339A1 (en) | 2024-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9597398B2 (en) | Formulations of bendamustine | |
| MX2023005763A (es) | Composiciones y metodos para la administracion dermica profunda de farmacos. | |
| US20230414617A1 (en) | Pharmaceutical composition comprising acid-base neutralization combination and application thereof | |
| JP2013181020A (ja) | 眼科用組成物 | |
| EP2421522A1 (de) | Paracetamol zur parenteralen verabreichung | |
| JP2011246383A (ja) | コンタクトレンズ装用者用疲れ目改善用眼科製剤 | |
| JOP20250146A1 (ar) | صيغ ليدوكايين منظمة قابلة للحقن وطرق تصنيعها | |
| TWI712429B (zh) | 水性醫藥組成物 | |
| CA3214630A1 (en) | Pharmaceutical composition comprising the compound smtp-7 | |
| RU2576612C2 (ru) | Трансдермальный абсорбируемый препарат | |
| EP3328357B1 (de) | Konzentrat enthaltend alprostadil | |
| JP2009161456A (ja) | 眼科用組成物 | |
| ATE386512T1 (de) | Vorgemischte amiodaron-haltige parenterale lösung und deren herstellungsverfahren | |
| JP5993620B2 (ja) | 点眼剤 | |
| DE102007014947B4 (de) | Stabilisierte wässrige Lösungen von Ergolinverbindungen | |
| US20170340647A1 (en) | Preservative-free Treprostinil Formulations and Methods and Devices for Use with Same | |
| MY202996A (en) | Ophthalmic composition for treatment of cornea wounds associated wth diabetes mellitus | |
| EP3328356A1 (de) | Konzentrat enthaltend alprostadil | |
| IL312623A (en) | Preserved formulations | |
| US20230241218A1 (en) | Formulations of bendamustine | |
| CN104257607A (zh) | 一种紫杉醇注射液及其制备方法 | |
| RU2013142835A (ru) | Способ лечения ишемического инсульта | |
| JPH06256212A (ja) | オーレオバシジン類のリポソーム製剤 |